NanoString Tech rallies on expanded availability for breast cancer diagnostic test

• NanoString Technologies (NSTG +16.2%) is enjoying a strong session after announcing that the Prosigna Breast Cancer Prognostic Gene Signature Assay will be available nationwide in Q1 2014.
• LH and DGX have "chosen to add the Prosigna Assay to their comprehensive suites of breast cancer diagnostic tests," NSTG notes. (PR)
• Meanwhile, Baird is out with an upgrade to Outperform from Neutral. Price target is now $18 (from $12).